The new treatment strategy of gene immunotherapy ; survivin gene induce cyototoxic lymphocyte and modify the function of dendritic cells

• Project/Area Number: 22791492
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Urology
• Research Institution: Wakayama Medical University
• Principal Investigator: FUJII Reona 和歌山県立医科大学, 医学部, 博士研究員 (30326368)
• Project Period (FY): 2010 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 腫瘍学 / 遺伝子免疫治療 / survivin / 樹状細胞;DC / 免疫治療 / 免疫遺伝子治療 / 泌尿器癌

Research Abstract

Survivin is a member of the inhibitor of apoptosis protein(IAP) family. The present study showed that survivin-specific cytotoxic T lymphocytes(CTLs) can be induced by dendritic cells : DCs transduced with the survivin gene by way of an adenoviral vector, and such CTLs showed cytotoxic activities against human urologic malignancies. Survivin is overexpressed in most cancer cells and chemotherapy-resistant cancer cells but is undetectable in normal tissues. This data suggested survivin is useful for chemotherapy-resistant cancer cells.
Survivin inhibits apoptosis and controls cell division. We showed the cell viability of DCs transduced with the survivin gene is longer than that of "normal" DCs. DCs transduced with the survivin gene can induce survivin-specific CTLs. The cytotoxic activity against bladder cancer cells(T-24) act long period.

Research Products

• [Presentation] 泌尿器科領域における遺伝子免疫治療の基礎的研究 (2011)
  • Author(s): 藤井令央奈
  • Organizer: 第32回癌免疫外科研究会
  • Year and Date: 2011-05-20